Please use symbol entry at top right of page to search

Pharmacovigilance and Drug Safety Software Market Worth $17.4 Billion by 2030: Grand View Research, Inc.

SAN FRANCISCO, June 20, 2022 /PRNewswire/ -- The global pharmacovigilance and drug safety software market size is anticipated to reach USD 17.4 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 10.5% from 2022 to 2030. The key factors driving the market growth include the increasing need to track and manage adverse drug reactions (ADR), comply with regulatory norms, increase adoption by end-users, interoperability, and product upgrades by key companies.

Grand View Research Logo

Key Industry Insights & Findings from the report:

  • The market was valued at USD 6.7 billion in 2021 and is expected to expand at a CAGR of 10.5% during the forecast period.
  • By functionality, the signal management segment held the largest revenue share in 2021. This growth is driven by the increasing use of machine learning and AI in signal detection and reporting.
  • Based on delivery mode, the on-demand segment dominated the market in 2021. This is owing to the greater flexibility offered by an on-demand software in terms of price, functionality, and scalability.
  • Based on end-use, the CROs and BPO segments are slated to witness lucrative growth owing to increasing adoption by outsourcing companies to curb healthcare costs.
  • By region, North America dominated the market in 2021 while the APAC market is anticipated to grow the fastest in the coming years. Asian countries, especially India and China, are also expected to observe remarkable growth in the coming years.
  • The market is relatively competitive owing to the presence of global multinational players. It is also consolidated to a certain extent with large multinational companies holding a notable share of the market.

Read 130-page market research report, "Pharmacovigilance And Drug Safety Software Market Size, Share & Trends Analysis Report By Functionality, By Delivery Mode (On Premise, On Demand), By End-use, By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Pharmacovigilance and Drug Safety Software Market Growth & Trends

Various end-users such as pharmaceutical, and biotechnology companies, are adopting pharmacovigilance and drug safety software for cost reduction and minimizing operational expenses by gradually shifting from being fully integrated pharmaceutical companies to sharing costs by collaborating with service providers. Outsourcing helps increase internal resource flexibility, improves timelines, and results in better outcomes in the short as well as long term. Outsourcing also helps achieve better pharmacovigilance (PV) through regulatory compliance, higher quality, better productivity, and improved strategic outcomes. This is expected to fuel market growth.

Pharmacovigilance and drug safety software vendors, in an attempt to ensure sustainability, are providing customized and end-to-end solutions to meet consumer needs. These vendors are also incorporating integrated technologies such as electronic data capture, AI, and interoperability, among others to enhance their offerings. Moreover, the combined pressures of volume, cost, and heightened demand for analytics are propelling industry stakeholders to adopt advanced technology to support their pharmacovigilance activities. Also, the fact that service providers are now operating via a flexible and variable pricing structure and achieving operational excellence through constant product updates is expected to boost usage rates over the forecast period.

Pharmacovigilance and Drug Safety Software Market Segmentation

Grand View Research has segmented the global pharmacovigilance and drug safety software market based on functionality, delivery mode, end-use, and region:

Pharmacovigilance and Drug Safety Software Market - Functionality Outlook (Revenue, USD Million, 2017 - 2030)

  • Case Processing
  • Signal Management
  • Safety Metrics & Others

Pharmacovigilance and Drug Safety Software Market - Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)

  • On-Premise
  • On-Demand

Pharmacovigilance and Drug Safety Software Market - End-use Outlook (Revenue, USD Million, 2017 - 2030)

  • Pharma & Biotech Companies
  • CRO
  • BPO
  • Others

Pharmacovigilance and Drug Safety Software Market - Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia

List of Key Players inĀ the Pharmacovigilance and Drug Safety Software Market

  • IQVIA
  • Accenture
  • Cognizant
  • Laboratory Corporation of America Holdings
  • IBM
  • ArisGlobal
  • ICON Plc.
  • Capgemini
  • Oracle
  • Parexel International Corporation

Check out more related studies published by Grand View Research:

  • Clinical Trials Matching Software Market - The global clinical trials matching software market size is expected to reach USD 396.1 million by 2030, based on a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 13.8% from 2022 to 2030. The significant increase in the number of ongoing clinical trials is likely to drive the market. In addition, the growing adoption of the clinical trial matching software catering to the clinical trials, along with the increased demand for virtual trials and automation in the healthcare sector are some of the key factors contributing to the market growth.
  • Medical Image Analysis Software Market - The global medical image analysis software market size is expected to reach USD 5.49 billion, expanding at a CAGR of 7.5% from 2022 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of chronic diseases creates demand for effective diagnostics solutions, which spurs the demand for medical image analysis software. The high growth is majorly attributed to a rise in the usage and uptake of image analysis solutions for diagnosis ring.
  • Patient Safety And Risk Management Software Market - The global patient safety and risk management software market size is expected to reach USD 3.1 billion by 2027, expanding at a CAGR of 11.0%, according to a new report by Grand View Research, Inc. The increasing need for efficient patient safety and risk assessment solutions to increase the efficiency of the healthcare providers and rising government initiatives to promote healthcare IT and improve the healthcare infrastructure are the key factors driving the market growth.

Browse through Grand View Research's Healthcare IT Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Grand View CompassĀ | Astra ESG Solutions
Follow Us: LinkedIn | Twitter

Logo:https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/pharmacovigilance-and-drug-safety-software-market-worth-17-4-billion-by-2030-grand-view-research-inc-301570990.html

SOURCE Grand View Research, Inc.

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.